Media Contacts
photo:Tulchan  Communications
Tulchan Communications
Tom Buchanan
020 7353 4200
Share this release
Share on: Twitter
Share on: Facebook
Share on: LinkedIn
Latest news
York,
25
July
2014

Tissue Regenix adds European bladder matrix patent to global exclusive licence portfolio

Tissue Regenix Group plc (AIM:TRX) (“Tissue Regenix” or “the Group”), the regenerative medical devices company, has received a decision to grant a European patent covering the use of its dCELL® technology in creating tissue implants for bladder repair.

The Group has exclusive access to a range of patents protecting its core processes in major markets, and is adding to these by working with its technology partner, the University of Leeds, to protect individual products and processes.

Tissue Regenix’s dCELL® decellularisation process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which is not rejected by the patient’s body, and which can then be used to repair diseased or worn-out body parts.

This is the latest patent covering the use of the dCELL® decellularisation process and follows a recent announcement in May 2014 that a similar patent, related to tissue matrices for bladder implantation, has been granted in the United States.

 

Antony Odell, CEO of Tissue Regenix
The global urology device market is one of the largest growth areas for the medical devices industry, and is estimated to be worth $8.6bn by 2022, driven by treatment demands for an ageing population.

As part of the global roll-out of our dCELL® technology, this latest European bladder patent adds to our ever-growing global portfolio, and helps Tissue Regenix achieve our aim of commercialising new ways to treat an array of urological disorders.
Antony Odell, CEO of Tissue Regenix

Tissue Regenix has offices in the UK and US and is concentrated on the global commercialisation of its dCELL® technology.